Please login to the form below

Not currently logged in
Email:
Password:

Enterprise Therapeutics appoints CEO

Dr John Ford will lead the UK drug discovery company

Enterprise Therapeutics Dr John FordBrighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.

In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.

Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.

Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.

“His expertise will complement the existing team and we are thrilled to have him on board.”

3rd November 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics